Cardiometabolic Disorders

Top Story

Apabetalone fails to benefit MACE, but ‘cautious optimism’ remains

November 18, 2019
Meeting NewsPerspective

DAPA-HF: Dapagliflozin’s HF benefits consistent regardless of age, symptom severity

November 17, 2019
PHILADELPHIA — Treatment with the SGLT2 inhibitor dapagliflozin reduced risk for CV death and worsening HF across a broad spectrum of age, independent of…
Meeting NewsPerspective

Dapagliflozin confers consistent benefit in HF without diabetes: DAPA-HF

November 16, 2019
PHILADELPHIA — New analyses of the DAPA-HF trial suggest that the benefits of the SGLT2 inhibitor dapagliflozin extend beyond its effects as a type 2 diabetes…
In the Journals

Oral blood cancer drug may worsen cardiometabolic health

November 13, 2019
An oral chemotherapy treatment used to treat myeloproliferative neoplasms is associated with substantial weight gain and increased systolic blood pressure, according to…
More Headlines »

New Options to Reduce Cardiovascular Events in ASCVD

This activity is supported by an independent educational grant from Amarin Pharma Inc.

This innovative, 30-minute, CME activity features 5 leading experts addressing complex issues when treating patients
More »
Meeting News

VIDEO: PCSK9 inhibitors show benefit in high-risk groups

July 13, 2019
More »

Ace the Case: A 17-Year-Old Boy Presents With Mild Periumbilical Abdominal Pain and Brownish Discoloration of the Skin Around His Neck

There is no commercial support for this activity.

This educational activity will utilize a case study to discuss the management of an obese, 17-year-old boy with mild…
More »